Record Q2 DAYBUE sales drive royalty upgrade for Neuren
Neuren Pharmaceuticals has confirmed that its partner Acadia Pharmaceuticals recorded record Q2 2026 net sales of US$125 million for DAYBUE (trofinetide), the highest quarterly total since launch and a result that has driven an upgrade to Neuren’s full-year royalty guidance.
The figure rose 30% on Q2 2025 and 24% on Q1 2026. Neuren’s Q2 royalty income reached US$12.9 million, up 34% year-on-year and 24% on the prior quarter.
On the back of the result, anticipated CY2026 royalties to Neuren were lifted to a range of US$53–56 million, from the previous US$50–54 million. Three forward catalysts underpin the thesis: the European launch, the Japan trial readout, and continued STIX adoption.
For investors, the mechanism is direct. A guidance upgrade from Acadia flows straight through to Neuren’s royalty stream.
When big ASX news breaks, our subscribers know first
Q2 sales performance and STIX-driven volume growth
Acadia reported that the quarter’s growth was almost entirely volume-driven. The primary driver was the uptake of DAYBUE STIX, the new powder formulation of trofinetide.
STIX became broadly available across the US from early April. By quarter end, 40% of all US DAYBUE patients were receiving the STIX formulation. Notably, approximately 45% of STIX demand came from new or returning patients.
Reflecting the momentum, Acadia raised its full-year 2026 DAYBUE net sales guidance to US$480–510 million, up from the prior range of US$460–490 million. Acadia also reaffirmed its 2028 DAYBUE net sales target of US$700 million.
The quarterly trajectory illustrates the acceleration in demand since launch.
| Quarter | DAYBUE Net Sales (US$m) | Trend |
|---|---|---|
| Q2 2024 | $85m | Early ramp |
| Q1 2026 | $101m | Steady growth |
| Q2 2026 | $125m | Record quarter |
Neuren CEO Commentary
“We are pleased to see an exceptional quarter for DAYBUE, with very strong sales volume growth reflecting the early success of STIX in the US, as well as achievement of the positive CHMP opinion – both important steps toward bringing trofinetide to more patients with Rett syndrome globally. Subject to approval being confirmed, we now look forward to Acadia’s anticipated European launch later this year,” said Jon Pilcher, Chief Executive Officer.
Europe: CHMP opinion opens path to major new market
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion at the end of June 2026, following a re-examination procedure. The opinion recommends that the European Commission grant a marketing authorisation for DAYBUE for the treatment of neurobehavioral symptoms of Rett syndrome in adults and paediatric patients aged five years and older.
The CHMP re-examination process that preceded the positive June 2026 opinion was initiated after an initial negative trend vote in early 2025, with Acadia’s concerns relating to treatment effect magnitude and long-term assessment rather than safety, a framing that ultimately supported a successful reversal.
If approved, the marketing authorisation would apply to all 27 EU member states, as well as Iceland, Liechtenstein and Norway. Commercial launch in Germany is anticipated in early Q4 2026, pending the European Commission approval decision.
Under the licence agreement for Europe, Neuren is entitled to the following economics:
-
US$35 million payment following first commercial sale
-
Sales milestone payments of up to US$170 million on achievement of escalating annual net sales thresholds
-
Tiered royalties from mid-teens to low-20s % of net sales
A European approval would add a materially new royalty and milestone stream on top of Neuren’s existing US-based income.
Understanding the royalty model — why partner sales matter for Neuren
Neuren has granted an exclusive worldwide license to Acadia Pharmaceuticals for the development and commercialisation of trofinetide. In practical terms, Acadia sells DAYBUE and manages the commercial operation, while Neuren earns royalties and milestone payments.
DAYBUE (trofinetide) oral solution is approved by the US Food and Drug Administration (FDA), Health Canada and the Ministry of Health in Israel for the treatment of Rett syndrome. DAYBUE STIX (trofinetide) powder is approved by the FDA.
Japan catalyst and the NNZ-2591 pipeline
In Japan, topline results of the ongoing trofinetide clinical trial remain on track for the September to November 2026 timeframe, with a regulatory submission in Japan anticipated in 2027.
Beyond DAYBUE, Neuren’s investigative drug candidate NNZ-2591 (ercanetide) is in clinical development as an oral solution treatment for multiple neurodevelopmental disorders, including Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome.
Each of these programmes has been granted orphan drug designation in the United States and the European Union, as well as Fast Track and Rare Pediatric Disease designations from the FDA. Neuren is currently conducting a Phase 3, randomised, double-blind, placebo-controlled trial (Koala) evaluating NNZ-2591 in children aged 3 to 12 years with Phelan-McDermid syndrome, alongside a 52-week open-label extension study. NNZ-2591 is also being developed for hypoxic ischemic encephalopathy (HIE).
The Phase 3 Koala trial is the world’s first Phase 3 study in Phelan-McDermid syndrome, an orphan indication with no approved treatment and no competing clinical programmes, positioning NNZ-2591 as a potential first-mover in a market where regulatory designations including FDA Fast Track and Rare Pediatric Disease status provide both development support and commercialisation incentives.
The pipeline provides growth optionality for investors beyond the existing DAYBUE royalty stream.
What comes next for Neuren investors
Several near-term catalysts are set to shape the outlook:
-
European Commission approval decision, with a German launch anticipated in early Q4 2026, which would trigger the US$35 million first commercial sale payment.
-
Japan trofinetide trial readout in the September to November 2026 window.
-
Japan regulatory submission anticipated in 2027.
-
Progression of the NNZ-2591 Phase 3 Koala trial.
With CY2026 royalty guidance strengthened to US$53–56 million and multiple catalysts pending, Neuren enters the second half of the year with an expanding royalty base and several potential inflection points ahead.
Don’t Miss the Next ASX Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at Big News Blast to get started today.